Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03953261 · ClinicalTrials.gov registry record · Phase 2
Effect of Curcumin on Systemic Lupus Erythematosus
A Phase 2 study, sponsored by Loma Linda University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT03953261: Clinical Trial Phase 2 study, sponsored by Loma Linda University.
NCT03953261 is a Phase 2 study that was terminated before completion, run by Loma Linda University. The registered enrollment target is 23 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03953261, a Phase 2 study, was terminated before completion, sponsored by Loma Linda University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subjects with rheumatoid arthritis as well as osteoarthritis have also found benefit for their disease activity.
Primary Outcome
Number of participants with change in SLEDAI by 2 points by Day 90
Interventions
- DRUG Curcumin supplement
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2019-09-01 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 2 |
Why NCT03953261 stopped before completion
NCT03953261 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 1 intervention - of which Curcumin supplement is the first listed.
NCT03953261 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03953261 about?
NCT03953261 is a clinical study titled "Effect of Curcumin on Systemic Lupus Erythematosus". The purpose of this investigator initiated study is to determine the efficacy of curcumin on disease activity of subjects with systemic lupus erythematous. Curcumin has been found to have anti-inflammatory effects and has been found to improve disease activity in lupus patients. In addition, subject...
What is the current status of trial NCT03953261?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2019-09-01. Estimated completion is 2022-04-13.
What interventions are being tested in trial NCT03953261?
The interventions under investigation include: Curcumin supplement (DRUG).
Who is sponsoring clinical trial NCT03953261?
This trial is sponsored by Loma Linda University, which has 237 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03953261's enrollment target sits among peer trials
23 1784th of 2000 higher than 211 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI